136 related articles for article (PubMed ID: 36036647)
1. Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC).
Dobritoiu F; Baltan A; Chefani A; Billingham K; Chenard MP; Vaziri R; Lacroix-Triki M; Waydelich A; Erb G; Andersson E; Cañamero M; Toro P; Wedden S; D'Arrigo C
Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):549-556. PubMed ID: 36036647
[TBL] [Abstract][Full Text] [Related]
2. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.
Peg V; López-García MÁ; Comerma L; Peiró G; García-Caballero T; López ÁC; Suárez-Gauthier A; Ruiz I; Rojo F
Future Oncol; 2021 Apr; 17(10):1209-1218. PubMed ID: 33289433
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
Hoda RS; Brogi E; Dos Anjos CH; Grabenstetter A; Ventura K; Patil S; Selenica P; Weigelt B; Reis-Filho JS; Traina T; Robson M; Norton L; Wen HY
Mod Pathol; 2020 Nov; 33(11):2221-2232. PubMed ID: 32612248
[TBL] [Abstract][Full Text] [Related]
5. Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
Badve SS; Penault-Llorca F; Reis-Filho JS; Deurloo R; Siziopikou KP; D'Arrigo C; Viale G
J Natl Cancer Inst; 2022 May; 114(5):664-675. PubMed ID: 34286340
[TBL] [Abstract][Full Text] [Related]
6. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
[TBL] [Abstract][Full Text] [Related]
7. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
[TBL] [Abstract][Full Text] [Related]
8. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Sun WY; Lee YK; Koo JS
J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
[TBL] [Abstract][Full Text] [Related]
9. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
[No Abstract] [Full Text] [Related]
10. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
[TBL] [Abstract][Full Text] [Related]
12. Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging.
Hoda RS; Brogi E; D'Alfonso TM; Grabenstetter A; Giri D; Hanna MG; Kuba MG; Murray MP; Vallejo CE; Zhang H; Reis-Filho JS; Wen HY
Arch Pathol Lab Med; 2021 Sep; 145(9):1132-1137. PubMed ID: 33417715
[TBL] [Abstract][Full Text] [Related]
13. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients.
Schmidt G; Guhl MM; Solomayer EF; Wagenpfeil G; Hammadeh ME; Juhasz-Boess I; Endrikat J; Kasoha M; Bohle RM
Arch Gynecol Obstet; 2022 Nov; 306(5):1689-1695. PubMed ID: 35377046
[TBL] [Abstract][Full Text] [Related]
15. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer.
Baek SH; Kim JH; Bae SJ; Ji JH; Lee Y; Jeong J; Cha YJ; Ahn SG
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804813
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Rozenblit M; Huang R; Danziger N; Hegde P; Alexander B; Ramkissoon S; Blenman K; Ross JS; Rimm DL; Pusztai L
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239417
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
19. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
[TBL] [Abstract][Full Text] [Related]
20. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
